Most current evidence supports the use of stimulants such as methylphenidate as the most effective treatment for Attention Deficit Hyperactivity Disorder. Unfortunately, an accurate appraisal of the therapeutic actions of stimulants, as well as the development of alternative treatment strategies, are hampered by limited understanding of the neuronal mechanisms that are affected by exposure to clinically relevant doses of these drugs. One major problem in assessing the relevancy of animal models to study the effects of these drugs is the difficulty in equating drug exposure conditions in humans and experimental animals. The profound effect of treatment conditions on the neurobiological responses to drugs has been extensively documented, and thus the translational utility of an animal model of drug usage critically depends on the degree to which the exposure profile simulates the human conditions. To enhance the potential translational value of animal models, we are developing an intravenous drug delivery methodology which enables an approximation in rats of the temporal profile of human plasma drug concentrations. The focus of the present proposal is to refine this methodology to simulate the temporal profile of plasma methylphenidate concentrations following oral administration that has been associated with the pharmacotherapy of Attention Deficit Hyperactivity Disorder. The exposure profile will include: a gradual increase in plasma methylphenidate to approximate the rise in drug associated with oral administration; day-long, constant or ascending plasma levels that have been associated with therapeutic efficacy; and the gradual decline in plasma drug corresponding to the human plasma half-life of about three hours. We will then apply this approach in rats in multidisciplinary studies using in vivo microdialysis and the 5-choice serial reaction time task to test the hypothesis that within-day-tolerance in efficacy that appears to occur when constant plasma levels of methylphenidate are maintained will be reflected in a decrease in the frontal cortex extracellular norepinephrine response and a corresponding decrease in attentional performance. The results of these studies will have important implications for understanding the mechanisms by which methylphenidate exerts its therapeutic effects and will provide a foundation and context for subsequent studies directed at the mechanisms by which this drug exerts its therapeutic effects. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21MH080001-02
Application #
7365252
Study Section
Special Emphasis Panel (ZRG1-IFCN-A (02))
Program Officer
Winsky, Lois M
Project Start
2007-03-01
Project End
2010-02-28
Budget Start
2008-03-01
Budget End
2010-02-28
Support Year
2
Fiscal Year
2008
Total Cost
$171,881
Indirect Cost
Name
University of California San Diego
Department
Psychiatry
Type
Schools of Medicine
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
D'Souza, Manoranjan S; Liechti, Matthias E; Ramirez-NiƱo, Ana M et al. (2011) The metabotropic glutamate 2/3 receptor agonist LY379268 blocked nicotine-induced increases in nucleus accumbens shell dopamine only in the presence of a nicotine-associated context in rats. Neuropsychopharmacology 36:2111-24
Ferreira, Manuel A R; O'Donovan, Michael C; Meng, Yan A et al. (2008) Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nat Genet 40:1056-8
El-Mallakh, Rif S; Ghaemi, S Nassir; Sagduyu, Kemal et al. (2008) Antidepressant-associated chronic irritable dysphoria (ACID) in STEP-BD patients. J Affect Disord 111:372-7
Sklar, P; Smoller, J W; Fan, J et al. (2008) Whole-genome association study of bipolar disorder. Mol Psychiatry 13:558-69
Marangell, Lauren B; Dennehy, Ellen B; Wisniewski, Stephen R et al. (2008) Case-control analyses of the impact of pharmacotherapy on prospectively observed suicide attempts and completed suicides in bipolar disorder: findings from STEP-BD. J Clin Psychiatry 69:916-22
Tohen, Mauricio; Bowden, Charles L; Smulevich, Anatoly B et al. (2008) Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes. Br J Psychiatry 192:135-43
Gonzalez, Jodi M; Prihoda, Thomas J (2007) A case study of psychodynamic group psychotherapy for bipolar disorder. Am J Psychother 61:405-22
Goldberg, Joseph F; Perlis, Roy H; Ghaemi, S Nassir et al. (2007) Adjunctive antidepressant use and symptomatic recovery among bipolar depressed patients with concomitant manic symptoms: findings from the STEP-BD. Am J Psychiatry 164:1348-55
Gonzalez, Jodi M; Thompson, Peter; Escamilla, Michael et al. (2007) Treatment characteristics and illness burden among European Americans, African Americans, and Latinos in the first 2,000 patients of the systematic treatment enhancement program for bipolar disorder. Psychopharmacol Bull 40:31-46
Miklowitz, David J; Otto, Michael W; Frank, Ellen et al. (2007) Psychosocial treatments for bipolar depression: a 1-year randomized trial from the Systematic Treatment Enhancement Program. Arch Gen Psychiatry 64:419-26

Showing the most recent 10 out of 52 publications